TrialThe Lancet. Oncology2016

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Andrew J Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.